

Investor News

Markus Georgi
Senior Vice President
Investor Relations & Sustainability

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
F +49 6172 608-2488
markus.georgi@fresenius.com
www.fresenius.com

June 7, 2022

Acceptance rate for scrip dividend of Fresenius reaches 40%

Fresenius has offered its shareholders a scrip dividend for the first time this year. This gave shareholders the opportunity to exchange part of their dividend entitlement for Fresenius shares during the subscription period from May 16 to May 30, 2022, and thus reinvest directly into the Company. Investors have chosen this option for a total of 40 % of shares carrying dividend rights. This means that around 147 million euros will remain within the company.

Based on the acceptance rate, around 4.7 million new shares will be issued, increasing the total number of Fresenius shares to 563,237,277.

The new shares are expected to be credited to the securities accounts of participating shareholders on June 13, 2022. Shareholders who have not or only partially exercised their option will receive the cash dividend also on or around June 13, 2022. The total cash distribution this year amounts to around 367 million euros.

The Else Kröner-Fresenius-Foundation has fully participated in the scrip dividend.

#

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN

Fresenius is a global healthcare group, providing products and services for dialysis, hospital and outpatient medical care. In 2021, Group sales were €37.5 billion. On March 31, 2022, the Fresenius Group had 317,242 employees worldwide.

For more information visit the Company's website at www.fresenius.com.
Follow us on Twitter: www.twitter.com/fresenius_ir.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the "United States") or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act") except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Rachel Empey, Rice Powell, Michael Sen, Dr. Ernst Wastler
Chairman of the Supervisory Board: Wolfgang Kirsch